Pelacarsen Fails to Cut Cardiovascular Events Despite Large Lp(a) Reduction
The La(a)HORIZON trial found pelacarsen lowered lipoprotein(a) by over 70% but did not reduce heart attacks, strokes or cardiovascular deaths.
Nov 7, 2026 · 4 min read
61 views